June 11, 2021
The mission of the Cystic Fibrosis Foundation is to cure cystic fibrosis and to provide all people with the disease the opportunity to lead full, productive lives by funding research and drug development, promoting individualized treatment, and ensuring access to high-quality, specialized care.
We continue to make tremendous progress towards these goals. Last year the U.S. Food and Drug Administration (FDA) approved the CFTR modulator Trikafta® (elexacaftor/tezacaftor/ivacaftor), which will eventually benefit more than 90 percent of people with CF. However, we will not rest until everyone has a therapy that addresses the underlying cause of their disease. With this commitment in mind, the Foundation launched our Path to a Cure, an ambitious research initiative to accelerate treatments for everyone with CF and ultimately deliver a cure. We intend to allocate a half billion dollars to the effort through 2025.
It is also critical to continue to develop new and improved treatments for complications from the disease. We are building on the current momentum, funding an innovative research portfolio and collaborating with top scientists from around the world to deliver the next generation of transformative breakthroughs in CF. To ensure that we continue to enable therapies to advance that otherwise would be unlikely to move beyond the lab and into clinical trials, we provide research funding and expertise to draw the best scientific minds and technologies into CF.
Our research funding has more than doubled over the last six years. Additionally, last year we funded approximately $191 million in laboratory research, preclinical drug development, clinical and real-world research, and high-quality, specialized care and training — more than at any other time in the history of the Foundation.